These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38279614)

  • 1. Clinicopathological definition, management and prognostic value of mogamulizumab-associated rash and other cutaneous events: A systematic review.
    Avallone G; Roccuzzo G; Pileri A; Agostinelli C; Maronese CA; Aquino C; Tavoletti G; Onida F; Fava P; Ribero S; Marzano AV; Berti E; Quaglino P; Alberti-Violetti S
    J Eur Acad Dermatol Venereol; 2024 Sep; 38(9):1738-1748. PubMed ID: 38279614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sézary Syndrome.
    Hirotsu KE; Neal TM; Khodadoust MS; Wang JY; Rieger KE; Strelo J; Hong E; Kim YH; Kwong BY
    JAMA Dermatol; 2021 Jun; 157(6):700-707. PubMed ID: 33881447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mogamulizumab-associated rash - Case series and review of the literature.
    Hansen I; Abeck F; Menz A; Schneider SW; Booken N
    J Dtsch Dermatol Ges; 2024 Aug; 22(8):1079-1086. PubMed ID: 38924340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathologic Characterization of Mogamulizumab-associated Rash.
    Wang JY; Hirotsu KE; Neal TM; Raghavan SS; Kwong BY; Khodadoust MS; Brown RA; Novoa RA; Kim YH; Rieger KE
    Am J Surg Pathol; 2020 Dec; 44(12):1666-1676. PubMed ID: 32976123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
    Kim YH; Bagot M; Pinter-Brown L; Rook AH; Porcu P; Horwitz SM; Whittaker S; Tokura Y; Vermeer M; Zinzani PL; Sokol L; Morris S; Kim EJ; Ortiz-Romero PL; Eradat H; Scarisbrick J; Tsianakas A; Elmets C; Dalle S; Fisher DC; Halwani A; Poligone B; Greer J; Fierro MT; Khot A; Moskowitz AJ; Musiek A; Shustov A; Pro B; Geskin LJ; Dwyer K; Moriya J; Leoni M; Humphrey JS; Hudgens S; Grebennik DO; Tobinai K; Duvic M;
    Lancet Oncol; 2018 Sep; 19(9):1192-1204. PubMed ID: 30100375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series.
    Trum NA; Zain J; Martinez XU; Parekh V; Afkhami M; Abdulla F; Carson KR; Rosen ST; Bennett CL; Querfeld C
    Br J Dermatol; 2022 Jan; 186(1):153-166. PubMed ID: 34427917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
    Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
    Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
    [No Abstract]   [Full Text] [Related]  

  • 8. Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.
    Tawa M; Kopp E; McCann S; Cantrell W
    Clin J Oncol Nurs; 2019 Aug; 23(4):E73-E80. PubMed ID: 31322628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
    Lewis DJ; Rook AH
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
    Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
    J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An occurrence of eosinophilic folliculitis and alopecia associated with a sustained complete response to mogamulizumab in Sézary syndrome: a case report.
    L'Orphelin JM
    Ther Adv Hematol; 2024; 15():20406207241235777. PubMed ID: 38456078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management.
    Musiek ACM; Rieger KE; Bagot M; Choi JN; Fisher DC; Guitart J; Haun PL; Horwitz SM; Huen AO; Kwong BY; Lacouture ME; Noor SJ; Rook AH; Seminario-Vidal L; Vermeer MH; Kim YH
    Dermatol Ther (Heidelb); 2022 Jan; 12(1):29-40. PubMed ID: 34816383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.
    Beylot-Barry M; Quereux G; Nardin C; Duval-Modeste AB; Dereure O; Dalac-Rat S; Dobos G; Pham-Ledard A; Ram-Wolff C; D'Incan M; Grange F; Braniste V; Bagot M
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1777-1784. PubMed ID: 37113040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure-Response Analysis for Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma.
    Mukai M; Mould D; Maeda H; Narushima K; Greene D
    J Clin Pharmacol; 2020 Jan; 60(1):50-57. PubMed ID: 31840837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.
    Duvic M; Pinter-Brown LC; Foss FM; Sokol L; Jorgensen JL; Challagundla P; Dwyer KM; Zhang X; Kurman MR; Ballerini R; Liu L; Kim YH
    Blood; 2015 Mar; 125(12):1883-9. PubMed ID: 25605368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas.
    Caruso L; Castellino A; Dessì D; Flenghi L; Giordano A; Ibatici A; Massone C; Pileri A; Proietti I; Pupo L; Quaglino P; Rupoli S; Zinzani PL
    Cancer Manag Res; 2022; 14():3205-3221. PubMed ID: 36444356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.
    Beygi S; Duran GE; Fernandez-Pol S; Rook AH; Kim YH; Khodadoust MS
    Blood; 2022 Jun; 139(26):3732-3736. PubMed ID: 35436328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of T-cell immunosequencing in distinguishing mycosis fungoides progression from treatment related cutaneous adverse events.
    Bhatti S; Joffe D; Banner L; Talasila S; Mandel J; Lee J; Porcu P; Nikbakht N
    Front Med (Lausanne); 2023; 10():1243459. PubMed ID: 38164221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.